LOX/LOXL in pulmonary fibrosis: potential therapeutic targets

Lysyl oxidase (LOX) and lysyl oxidase-like proteins (LOXL), a family of extracellular matrix (ECM) crosslinking enzymes that have been recognised as playing an important role in fibrogenesis for more than 40 years, are logical targets for antifibrotic treatments. Pulmonary fibrosis, especially idiop...

Full description

Saved in:
Bibliographic Details
Published inJournal of drug targeting Vol. 27; no. 7; pp. 790 - 796
Main Authors Chen, Lijun, Li, Shifeng, Li, Wande
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 09.08.2019
Subjects
idiopathic pulmonary fibrosis
Lysyl oxidase
lysyl oxidase-like proteins
pulmonary fibrosis
therapeutic targets
lysyl oxidase-like proteins
idiopathic pulmonary fibrosis
therapeutic targets
Lysyl oxidase
pulmonary fibrosis
Online AccessGet full text

Cover

More Information
Summary:Lysyl oxidase (LOX) and lysyl oxidase-like proteins (LOXL), a family of extracellular matrix (ECM) crosslinking enzymes that have been recognised as playing an important role in fibrogenesis for more than 40 years, are logical targets for antifibrotic treatments. Pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), is a progressive and lethal disease characterised by excessive deposition of ECM in the lung parenchyma. In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis. Although these findings are controversial and require further validation, LOX/LOXL1/LOXL2 as potential therapeutic targets for IPF deserve continued attention. So far to our knowledge, LOXL3 or LOXL4 has not clearly shown specific therapeutic potential.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1061-186X
1029-2330
DOI:10.1080/1061186X.2018.1550649